Herd immunity after pneumococcal conjugate vaccination

Lancet

Volumn 370, Issue 9583, 2007, Pages 218-219

  Albrich, Werner C ^a,b   Madhi, Shabir A ^a   Lafond, Kathryn E ^b   Klugman, Keith P ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESEARCH; EPIDEMIC; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LETTER; LOBAR PNEUMONIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUBERCULOSIS; VACCINATION;

EID: 34447512669     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61119-2     Document Type: Letter

References (5)

1. Grijalva C., Nuorti J., Arbogast P., Martin S., Edwards K., and Griffin M. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (2007) 1179-1186
2. Klugman K., Madhi S., Huebner R., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003) 1341-1348
3. Metlay J., Fishman N., Joffe M., and Edelstein P. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 24 (2006) 468-475
4. Lexau C., Lynfield R., Danila R., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Jama 294 (2005) 2043-2051
5. Madhi S., Kuwanda L., Cutland C., and Klugman K. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 40 (2005) 1511-1518